湖北地区房颤患者VKORC1、CYP2C9基因多态性及其对华法林用量的影响  

Impact of VKORC1 and CYP2C9 Polymorphism on Warfarin Dosage in Patients with Atrial Fibrillation in HuBei

作　　者：黄爱霞[1] 乔斌[2] 

机构地区：[1]湖北省监利县人民医院检验科,监利433300 [2]武汉大学人民医院检验科,武汉430060

出　　处：《微循环学杂志》2014年第4期44-48,共5页Chinese Journal of Microcirculation

摘　　要：目的:检测房颤患者维生素K环氧化物还原酶复合物1基因(VKORC1)和细胞色素P450酶2C9基因(CYP2C9)多态性及其对临床使用华法林用量的影响。方法:选择口服华法林抗凝治疗的房颤患者94例,采用PCR扩增和DNA直接测序技术检测患者VKORC1和CYP2C9基因型,同时记录不同基因型患者华法林日用量,比较不同基因型房颤患者华法林日用量的统计学差异。结果:94例房颤患者检出VKORC1 AA型84例,VKORC1AG型10例,CYP2C9*1/*1型88例,CYP2C9*1/*3型6例。不同VKORC1、CYP2C9基因型房颤患者华法林用量不同,VKORC1AA型并CYP2C9*1/*1型和VKORC1AG型并CYP2C9*1/*1型患者华法林日用量均高于VKORC1AA型并CYP2C9*1/*3型患者,VKORC1AA型并CYP2C9*1/*1型患者华法林用量又高于VKORC1AG型并CYP2C9*1/*1型患者。结论:湖北地区房颤患者基因型主要为VKORC1AA型与CYP2C9*1/*1型,少量VKORC1AG型与CYP2C9*1/*3型。VKORC1、CYP2C9基因型是华法林用量的重要影响因素。Objective：To assess the impact of VKORC1 and CYP2C9 polymorphism on warfarin dosage in pa-tients with atrial fibrillation.Method：Collecting 94 patients of atrial fibrillation using warfarin anticoagulant stability of the standard（INR 2.0-3.0）.The genotype of VKORC1 and CYP2C9 were detected by PCR amplification and direct sequencing,and the dosage of warfarin of the patients were recorded and analysed between different geno-types.Results：94 cases were genotyping,84 were VKORC1 AA,10 were VKORC1 AG,88 were CYP2C9＊1/＊1, 6 were CYP2C9＊1/＊3.The mean warfarin doses of VKORC1 AA with CYP2C9＊1/＊1 and VKORC1 AG with CYP2C9＊1/＊1 were significant more than VKORC1 AA with CYP2C9＊1/＊3;The mean warfarin doses ofVKORC1 AA with CYP2C9＊1/＊1 was significant more than VKORC1 AG with CYP2C9＊1/＊1.Conclusion：The major genotypes of atrial fibrillation related gene were VKORC1 AA and CYP2C9＊1/＊1 in HuBei.The geno-type of VKORC1 and CYP2C9 were the important influencing factors for warfarin doses of atrial fibrillation.

关 键 词：房颤 华法林 VKORC1 CYP2C9 

分 类 号：R446.9[医药卫生—诊断学]